Impact of the ablation technique on release of the neuronal injury marker S100B during pulmonary vein isolation
Standard
Impact of the ablation technique on release of the neuronal injury marker S100B during pulmonary vein isolation. / Scherschel, Katharina; Hedenus, Katja; Jungen, Christiane; Münkler, Paula; Willems, Stephan; Anwar, Omar; Klatt, Niklas; Eickholt, Christian; Meyer, Christian.
in: EUROPACE, Jahrgang 22, Nr. 10, 01.10.2020, S. 1502-1508.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of the ablation technique on release of the neuronal injury marker S100B during pulmonary vein isolation
AU - Scherschel, Katharina
AU - Hedenus, Katja
AU - Jungen, Christiane
AU - Münkler, Paula
AU - Willems, Stephan
AU - Anwar, Omar
AU - Klatt, Niklas
AU - Eickholt, Christian
AU - Meyer, Christian
N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - AIMS: S100B, a well-known damage-associated molecular pattern protein is released acutely by central and peripheral nerves and upon concomitant denervation in pulmonary vein isolation (PVI). We aimed to investigate whether the ablation technique used for PVI impacts S100B release in patients with paroxysmal atrial fibrillation (AF).METHODS AND RESULTS: The study population consisted of 73 consecutive patients (age: 62.7 ± 10.9 years, 54.8% males) undergoing first-time PVI with either radiofrequency (RF; n = 30) or cryoballoon (CB; n = 43) for paroxysmal AF. S100B determined from venous plasma samples taken immediately before and after PVI increased from 33.5 ± 1.8 to 91.1 ± 5.3 pg/mL (P < 0.0001). S100B release in patients undergoing CB-PVI was 3.9 times higher compared to patients with RF-PVI (ΔS100B: 21.1 ± 2.7 vs. 83.1 ± 5.2 pg/mL, P < 0.0001). During a mean follow-up of 314 ± 186 days, AF recurrences were observed in 18/71 (25.4%) patients (RF-PVI: n = 9/28, CB-PVI: n = 9/43). Univariate Cox regression analysis indicated that an increase in S100B was associated with higher freedom from AF in follow-up (hazard ratio per 10 pg/mL release of S100B: 0.83; 95% confidence interval: 0.72-0.95; P = 0.007).CONCLUSION: The ablation technique used for PVI has an impact on the release of S100B, a well-established biomarker for neural damage.
AB - AIMS: S100B, a well-known damage-associated molecular pattern protein is released acutely by central and peripheral nerves and upon concomitant denervation in pulmonary vein isolation (PVI). We aimed to investigate whether the ablation technique used for PVI impacts S100B release in patients with paroxysmal atrial fibrillation (AF).METHODS AND RESULTS: The study population consisted of 73 consecutive patients (age: 62.7 ± 10.9 years, 54.8% males) undergoing first-time PVI with either radiofrequency (RF; n = 30) or cryoballoon (CB; n = 43) for paroxysmal AF. S100B determined from venous plasma samples taken immediately before and after PVI increased from 33.5 ± 1.8 to 91.1 ± 5.3 pg/mL (P < 0.0001). S100B release in patients undergoing CB-PVI was 3.9 times higher compared to patients with RF-PVI (ΔS100B: 21.1 ± 2.7 vs. 83.1 ± 5.2 pg/mL, P < 0.0001). During a mean follow-up of 314 ± 186 days, AF recurrences were observed in 18/71 (25.4%) patients (RF-PVI: n = 9/28, CB-PVI: n = 9/43). Univariate Cox regression analysis indicated that an increase in S100B was associated with higher freedom from AF in follow-up (hazard ratio per 10 pg/mL release of S100B: 0.83; 95% confidence interval: 0.72-0.95; P = 0.007).CONCLUSION: The ablation technique used for PVI has an impact on the release of S100B, a well-established biomarker for neural damage.
KW - Ablation Techniques
KW - Aged
KW - Anticoagulants
KW - Atrial Fibrillation/diagnosis
KW - Biomarkers
KW - Catheter Ablation/adverse effects
KW - Cryosurgery/adverse effects
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Pulmonary Veins/surgery
KW - S100 Calcium Binding Protein beta Subunit
KW - Treatment Outcome
U2 - 10.1093/europace/euaa159
DO - 10.1093/europace/euaa159
M3 - SCORING: Journal article
C2 - 32830253
VL - 22
SP - 1502
EP - 1508
JO - EUROPACE
JF - EUROPACE
SN - 1099-5129
IS - 10
ER -